ArticleTheranostics2020
Synthesis and preliminary studies of
Open access · goldAbstract read
In one paragraph
Article in Theranostics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.5field-weighted citation impact, top 20% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 19 citations in OpenAlex.
- Imaging poly(ADP-ribose) polymerase-1 (PARP1)Acta pharmaceutica Sinica. B · 2025Article
- Novel Isoindolin-1-one Derivatives as Metabotropic Glutamate Receptor Positive Allosteric Modulators.ACS medicinal chemistry letters · 2025Article
- Radiosynthesis and Evaluation of 11C-Labeled Isoindolone-Based Positive Allosteric Modulators for Positron Emission Tomography Imaging of Metabotropic Glutamate Receptor 2.ACS pharmacology & translational science · 2024Article
- Distribution of [Naunyn-Schmiedeberg's archives of pharmacology · 2023Article
- Discovery of MK-8768, a Potent and Selective mGluR2 Negative Allosteric Modulator.ACS medicinal chemistry letters · 2023Article
- Discovery of [ACS medicinal chemistry letters · 2023Article
- Positron Emission Tomography Assessments of Phosphodiesterase 10A in Patients With Schizophrenia.Schizophrenia bulletin · 2023Article
- Imaging of Transmembrane AMPA Receptor Regulatory Proteins by Positron Emission Tomography.Journal of medicinal chemistry · 2022Article
- Synthesis and Characterization of 5-(2-Fluoro-4-[Journal of medicinal chemistry · 2022Article
- Upregulation of Striatal Metabotropic Glutamate Receptor Subtype 1 (mGluR1) in Rats with Excessive Glutamate Release Induced by N-Acetylcysteine.Neurotoxicity research · 2022Article
- The Repertoire of Small-Molecule PET Probes for Neuroinflammation Imaging: Challenges and Opportunities beyond TSPO.Journal of medicinal chemistry · 2021Review
- Development of a triazolobenzodiazepine-based PET probe for subtype-selective vasopressin 1A receptor imaging.Pharmacological research · 2021Article
- Synthesis and Characterization of [Molecular imaging and biology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors at 7 institutions in 3 countries.
Xiaofei ZhangDivision of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital & Department of Radiology, Harvard Medical School, Boston, MA, 02114, USA.
Yiding ZhangDepartment of Radiopharmaceuticals Development, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, 4-9-1 Anagawa, Inage-ku, Chiba 263-8555, Japan.
Zhen ChenDivision of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital & Department of Radiology, Harvard Medical School, Boston, MA, 02114, USA.
Tuo ShaoDivision of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital & Department of Radiology, Harvard Medical School, Boston, MA, 02114, USA.
Richard VanDepartment of Chemistry and Biochemistry, University of Oklahoma, Norman, Oklahoma 73019, United States.
Katsushi KumataDepartment of Radiopharmaceuticals Development, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, 4-9-1 Anagawa, Inage-ku, Chiba 263-8555, Japan.
Xiaoyun DengDivision of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital & Department of Radiology, Harvard Medical School, Boston, MA, 02114, USA.
Hualong FuDivision of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital & Department of Radiology, Harvard Medical School, Boston, MA, 02114, USA.
Tomoteru YamasakiDepartment of Radiopharmaceuticals Development, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, 4-9-1 Anagawa, Inage-ku, Chiba 263-8555, Japan.
Jian RongDivision of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital & Department of Radiology, Harvard Medical School, Boston, MA, 02114, USA.
Kuan HuDepartment of Radiopharmaceuticals Development, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, 4-9-1 Anagawa, Inage-ku, Chiba 263-8555, Japan.
Akiko HatoriDepartment of Radiopharmaceuticals Development, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, 4-9-1 Anagawa, Inage-ku, Chiba 263-8555, Japan.
Lin XieDepartment of Radiopharmaceuticals Development, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, 4-9-1 Anagawa, Inage-ku, Chiba 263-8555, Japan.
Qingzhen YuDivision of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital & Department of Radiology, Harvard Medical School, Boston, MA, 02114, USA.
Weijian YeDepartment of Nuclear Medicine and PET/CT-MRI Center, The First Affiliated Hospital of Jinan University, 613 West Huangpu Road, Tianhe District, Guangzhou 510630, China.
Hao XuDepartment of Nuclear Medicine and PET/CT-MRI Center, The First Affiliated Hospital of Jinan University, 613 West Huangpu Road, Tianhe District, Guangzhou 510630, China.
Douglas J ShefflerCancer Metabolism and Signaling Networks Program and Conrad Prebys Center for Chemical Genomics, Sanford-Burnham Prebys Medical Discovery Institute, La Jolla, California 92037, United States.
Nicholas D P CosfordCancer Metabolism and Signaling Networks Program and Conrad Prebys Center for Chemical Genomics, Sanford-Burnham Prebys Medical Discovery Institute, La Jolla, California 92037, United States.
Yihan ShaoDepartment of Chemistry and Biochemistry, University of Oklahoma, Norman, Oklahoma 73019, United States.
Pingping TangState Key Laboratory and Institute of Elemento-Organic Chemistry, Collaborative Innovation Center of Chemical Science and Engineering, Nankai University, Tianjin 300071, China.
Lu WangDivision of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital & Department of Radiology, Harvard Medical School, Boston, MA, 02114, USA.
Ming-Rong ZhangDepartment of Radiopharmaceuticals Development, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, 4-9-1 Anagawa, Inage-ku, Chiba 263-8555, Japan.
Steven H LiangDivision of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital & Department of Radiology, Harvard Medical School, Boston, MA, 02114, USA.
Harvard University · USNational Institutes for Quantum and Radiological Science and Technology · JPFirst Affiliated Hospital of Jinan University · CNNankai University · CNSanford Burnham Prebys Medical Discovery Institute · USUniversity of Oklahoma · USMassachusetts General Hospital · US
Funding
PET ligand development for mGlu2 based on negative allosteric modulatorsR01MH117125 · NIMH · MASSACHUSETTS GENERAL HOSPITAL · PI LIANG, STEVEN H · 2018 to 2020
$1.6MNIMH NIH HHS R01 MH117125
Abstract
Selective modulation of metabotropic glutamate receptor 2 (mGlu
Indexed as
Allosteric RegulationAnimalsAutoradiographyBrainCarbon RadioisotopesLigandsMaleModels, AnimalNaphthyridinesPositron-Emission TomographyRadioligand AssayRadiopharmaceuticalsRatsReceptors, Metabotropic GlutamateTissue DistributionCarbon-11Carbon RadioisotopesLigandsmetabotropic glutamate receptor 2NaphthyridinesRadiopharmaceuticalsReceptors, Metabotropic Glutamate11Cmetabotropic glutamate receptor 2mGlu2negative allosteric modulatorpositron emission tomography
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.